Dr Martens, the renowned British bootmaker, has revealed the price for its upcoming initial public offering (IPO), valuing the company at an astonishing £3.7 billion. This exceeds the initial expected value of £3.5 billion, highlighting the brand’s incredible achievement. The shares will be offered at 370p each on the London Stock Exchange.

CEO Kenny Wilson expressed his immense satisfaction with the significant interest and support received from institutional investors. He also emphasized the successful transformation of Dr Martens and the exciting prospects for future growth. Being listed as a London company not only solidifies its position as a successful public limited company but also provides opportunities for further expansion of the brand globally.

The IPO offer comprises 350 million shares, which will be sold by the majority shareholder, IngreLux S.àr.l., as well as other existing shareholders. This represents 35% of Dr Martens’ issued share capital upon admission, totaling £1.295 billion. The offer received tremendous demand, surpassing expectations by up to eight times. Moreover, the principal shareholder has made an additional 52.5 million shares available, which, if fully taken up, would account for over 40% of Dr Martens’ issued share capital.

Conditional trading of the shares commenced on Friday under the ticker symbol DOCS, with full trading set to begin on February 3. This marks a significant milestone for Dr Martens, demonstrating the strong investor interest in the brand and its potential for future growth in the fashion industry.

Useful Links:
1. Dr Martens Official Website
2. London Stock Exchange